Aldose Reductase

Aldose Reductase

Aldose reductase is a tiny, cytosolic, monomeric enzyme that is a member of the aldo-keto reductase superfamily. Numerous aromatic and aliphatic carbonyl compounds are reduced by aldose reductase using the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH). It has been linked to the emergence of diabetic and galactosemic complications that affect the kidney, nerves, lens, and retina.

Aldose reductase is a crucial polyol pathway enzyme that, when activated under hyperglycemic conditions, causes the development of chronic diabetic complications. It is also a key factor in the promotion of inflammatory and cytotoxic conditions, even when blood sugar levels are normal. Aldose reductase is a fantastic drug target, and there is a lot of work being done to identify new substances that can inhibit it.

Aldose Reductase related products

Structure Cat No. Product Name CAS No. Product Description
V73734 6,7-Dihydroxy-4-coumarinylacetic acid 88404-14-2 6,7-Dihydroxy-4-coumarinylacetic acid is a potent and specific inhibitor of ALR2.
V73729 6-Hydroxyluteolin 18003-33-3 6-Hydroxyluteolin (Compound 17) is a flavonoid compound.
V73733 AKR1B10-IN-1 2136579-33-2 AKR1B10-IN-1 is a potent inhibitor of AKR1B10 with IC50 of 3.5 nM.
V77870 AKR1C3-IN-10 AKR1C3-IN-10 (compound 5r) is a selective AKR1C3 inhibitor (IC50=51 nM).
V73732 AKR1C3-IN-9 2924824-43-9 AKR1C3-IN-9 is a selective inhibitor of aldehyde-keto reductase 1C3 (AKR1C3) with IC50 of 8.92 nM.
V73731 ALR2-IN-1 2799695-54-6 ALR2-IN-1 is a potent and specific inhibitor of ALR2 (IC50=1.42 μM).
V80090 ALR2-IN-2 ALR2-IN-2 is a potent aldose reductase (ALR2) inhibitor, with IC50s of 27 nM and 228 nM for rat ALR2 and ALR1 inhibition, respectively.
V80087 ALR2-IN-3 ALR2-IN-2 is a potent aldose reductase (ALR2) inhibitor, with IC50s of 22 nM and 116 nM for rat ALR2 and ALR1 inhibition, respectively.
V37639 AT-007 2170729-29-8 AT-007 is a novel and orally bioactive central nervous system (CNS) penetrant Aldose Reductase inhibitor for treatment of Galactosemia with an IC50 value of 100 pM.
V73730 Ganoderic acid C6 105742-76-5 Ganoderic acid C6 has aldose reductase inhibitory activity.
V73735 Ganoderic acid Df 1352033-73-8 Ganoderic acid Df is a lanosterane-type triterpenoid compound that can be extracted from the fruiting bodies of Ganoderma lucidum.
V2013 Isoliquiritigenin (GU17) 961-29-5 Isoliquiritigenin (also known as ISL; GU17; Isoliquiritigen) is a naturally occuring chalcone compound and NLRP3 antagonist found in licorice root and several other plants that displays antioxidant, anti-inflammatory, and antitumor activities as well as hepatoprotection against steatosis-induced oxidative stress.
V24126 Lidorestat 245116-90-9 Lidorestat (EML-676;ALN-101; IDD-000676-01;IDD-676) is a novel and potent aldose reductase inhibitor which isorally bioactive and can be used to treat chronic diabetes complications.
V73738 Myrciacetin 203734-35-4 Myrciacetin is a flavonoid.
V28701 Poliumoside 94079-81-9 Poliumoside possesses significant antiinflammatory and antioxidant activity, It is a novel and potent natural compound and isisolated fromBrandisia hanceistems and leaves.
V5317 Ponalrestat 72702-95-5 Ponalrestat (MK-538; ICI 128436; Statil) is a novel and potent aldose reductase inhibitor which inhibits the conversion of glucose to sorbitol.
V12303 Ranirestat 147254-64-6 Ranirestat (AS-3201; SX-3201) is a novel, oral and potent aldose reductase inhibitorwith the potential for the treatment of diabetic neuropathy.
V14560 Tolrestat (AY-27773) 82964-04-3 Tolrestat is a potent, orally bioavailable aldose reductase inhibitor (antagonist) with IC50 of 35 nM.
V28535 Zopolrestat 110703-94-1 Zopolrestat (CP-73850; CP73850) is a novel and potent aldose reductase inhibitor (IC50 = 3.1 nM) with the potentialfor the treatment of diabetic nephropathy and diabetes.
V73736 β-Glucogallin (1-O-Galloyl-β-D-glucose) 13405-60-2 β-Glucogallin is a potent and specific aldose reductase (AKR1B1) inhibitor.
Contact Us Back to top